Fully Closed-Loop Glucose Control in Noncritical Care Settings—A Randomised, Controlled Two-Centre Study

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 350-OR
Author(s):  
LIA BALLY ◽  
HOOD THABIT ◽  
SARA HARTNELL ◽  
EVELINE ANDEREGGEN ◽  
YUE RUAN ◽  
...  
Keyword(s):  
Glucose Control ◽  
Closed Loop ◽  
Centre Study ◽  
Randomised Controlled

scholarly journals Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial

Diabetologia ◽  
2017 ◽  
Vol 60 (11) ◽  
pp. 2157-2167 ◽  
Author(s):  
Klemen Dovc ◽  
Maddalena Macedoni ◽  
Natasa Bratina ◽  
Dusanka Lepej ◽  
Revital Nimri ◽  
...  
Keyword(s):  
Physical Activity ◽  
Type 1 Diabetes ◽  
Young People ◽  
Glucose Control ◽  
Closed Loop ◽  
Crossover Trial ◽  
Randomised Controlled

scholarly journals Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol

BMJ Open ◽  
2018 ◽  
Vol 8 (8) ◽  
pp. e020275 ◽  
Author(s):  
Martin de Bock ◽  
Sybil A McAuley ◽  
Mary Binsu Abraham ◽  
Grant Smith ◽  
Jennifer Nicholas ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glucose Control ◽  
Standard Therapy ◽  
Closed Loop ◽  
Insulin Pump ◽  
Controlled Trial ◽  
Artificial Pancreas ◽  
Insulin Delivery ◽  
Randomised Controlled

IntroductionAutomated insulin delivery (also known as closed loop, or artificial pancreas) has shown potential to improve glycaemic control and quality of life in people with type 1 diabetes (T1D). Automated insulin delivery devices incorporate an insulin pump with continuous glucose monitoring(CGM) and an algorithm, and adjust insulin in real time. This study aims to establish the safety and efficacy of a hybrid closed-loop (HCL) system in a long-term outpatient trial in people with T1D aged 12 –<25 years of age, and compare outcomes with standard therapy for T1D as used in the contemporary community.Methods and analysisThis is an open-label, multicentre, 6-month, randomised controlled home trial to test the MiniMed Medtronic 670G system (HCL) in people with T1D aged 12 –<25 years, and compare it to standard care (multiple daily injections or continuous subcutaneous insulin infusion (CSII), with or without CGM). Following a run-in period including diabetes and carbohydrate counting education, dosage optimisation and baseline glucose control data collection, participants are randomised to either HCL or to continue on their current treatment regimen. The primary aim of the study is to compare the proportion of time spent in target sensor glucose range (3.9–10.0 mmol/L) on HCL versus standard therapy. Secondary aims include a range of glucose control parameters, psychosocial measures, health economic measures, biomarker status, user/technology interactions and healthcare professional expectations. Analysis will be intention to treat. A study in adults with an aligned design is being conducted in parallel to this trial.Ethics and disseminationEthics committee permissions were gained from respective institutional review boards. The findings of the study will provide high-quality evidence on the role of HCL in clinical practice.

Closed-Loop System Improves Glucose Control

2010 ◽  
Vol 40 (4) ◽  
pp. 42-43
Author(s):  
MIRIAM E. TUCKER
Keyword(s):  
Glucose Control ◽  
Closed Loop ◽  
Loop System ◽  
Closed Loop System

Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with Type 1 diabetes

2010 ◽  
Vol 27 (4) ◽  
pp. 480-484 ◽  
Author(s):  
D. Elleri ◽  
J. M. Allen ◽  
M. Nodale ◽  
M. E. Wilinska ◽  
C. L. Acerini ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Glucose Control ◽  
Insulin Infusion ◽  
Closed Loop

scholarly journals Closed-loop management of inpatient hyperglycaemia

2019 ◽  
Vol 80 (11) ◽  
pp. 665-669
Author(s):  
CK Boughton ◽  
R Hovorka
Keyword(s):  
Health Care ◽  
Insulin Therapy ◽  
Health Care Professionals ◽  
Glucose Control ◽  
Closed Loop ◽  
Diabetes Management ◽  
Inpatient Setting ◽  
Glucose Levels ◽  
Closed Loop Systems ◽  
Inpatient Diabetes

The prevalence of diabetes in the inpatient setting is increasing, and suboptimal glucose control in hospital is associated with increased morbidity and mortality. Attaining the recommended glucose levels is challenging with standard insulin therapy. Hypoglycaemia and hyperglycaemia are common and diabetes management in hospital can be a considerable workload burden for health-care professionals. Fully automated insulin delivery (closed-loop) has been shown to be safe, and achieves superior glucose control than standard insulin therapy in the hospital, including in those patients receiving haemodialysis and enteral or parenteral nutrition where glucose control can be particularly challenging. Evidence that the improved glucose control achieved using closed-loop systems can translate into improved clinical outcomes for patients is key to support widespread adoption of this technology. The closed-loop approach has the potential to provide a paradigm shift in the management of inpatient diabetes, particularly in the most challenging inpatient populations, and may reduce staff work burden and the health-care costs associated with inpatient diabetes.

Grading System to Assess Clinical Performance of Closed-Loop Glucose Control

2005 ◽  
Vol 7 (1) ◽  
pp. 72-82 ◽  
Author(s):  
Ludovic J. Chassin ◽  
Malgorzata E. Wilinska ◽  
Roman Hovorka
Keyword(s):  
Glucose Control ◽  
Closed Loop ◽  
Clinical Performance ◽  
Grading System
Sign in / Sign up

Export Citation Format

Share Document